{"classes":[{"categories":[{"measurements":[{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"0.9","upperLimit":"NA","value":"1.4"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"1.4","upperLimit":"NA","value":"4.0"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG002","lowerLimit":"1.2","upperLimit":"NA","value":"2.3"},{"groupId":"OG003","lowerLimit":"1.1","upperLimit":"3.2","value":"1.5"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG004","lowerLimit":"1.2","upperLimit":"NA","value":"1.3"},{"groupId":"OG005","lowerLimit":"4.6","upperLimit":"13.3","value":"6.7"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG006","lowerLimit":"9.8","upperLimit":"NA","value":"14.6"},{"comment":"PFS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG007","lowerLimit":"4.5","upperLimit":"NA","value":"NA"},{"groupId":"OG008","lowerLimit":"3.2","upperLimit":"6.5","value":"4.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"11"}],"units":"Participants"}],"description":"Time from first dose of study drug to disease progression (PD) or death due to any cause. Participants who undergo surgical resection of target or non-target lesions, who have received other anticancer treatments, including surgical resection or radiation (other than palliative radiation to pre-existing bone metastases'), or who do not have a documented date of progression or death due to any cause will be censored at the date of the last assessment. Disease progression per RECIST v1.1 is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Dose escalation with rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG000","title":"Part 1 Cohort 1 Escalation Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG001","title":"Part 1 Cohort 2 Escalation Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC6 at Day 1 of each 21-day cycle.","id":"OG002","title":"Part 1 Cohort 3 Escalation Rebastinib 100 mg + Carboplatin AUC6"},{"description":"Dose expansion in TNBC participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG003","title":"Part 2 Cohort 1 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in TNBC participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG004","title":"Part 2 Cohort 1 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG005","title":"Part 2 Cohort 2 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG006","title":"Part 2 Cohort 2 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG007","title":"Part 2 Cohort 3 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG008","title":"Part 2 Cohort 3 Expansion Rebastinib 100 mg + Carboplatin AUC5"}],"paramType":"MEDIAN","populationDescription":"mITT participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"First Dose of Study Drug to PD or Death due to Any Cause (up to 1.63 years)","title":"Progression-free-survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}